DICE Therapeutics
Gary Brandt is an experienced professional in computational and medicinal chemistry, currently serving as Executive Director of Computational Chemistry at DICE Therapeutics, Inc., with a progression from Senior Director and Director roles since June 2021. Prior to DICE, Gary held the position of Director of Computational and Medicinal Chemistry at Bolt Biotherapeutics, focusing on the design of small molecule components of ISACs, and acted as Director and Head of the Department of Medicinal Chemistry at BlackThorn Therapeutics, contributing to the care of patients with neurobehavioral disorders. Gary's earlier roles included various positions at Theravance Biopharma, where strategic influence and research in locally restricted compounds were key, as well as post-doctoral research at Emory University on anti-viral agents and a research associate role at Deciphera Pharmaceuticals working on kinase inhibitors. Gary holds a Ph.D. in Medicinal Chemistry from The University of Kansas and a B.S. in Chemistry from Georgia State University.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.